tbuckley/cabot-search huggingface dataset:
261 VASCULAR ENDOTHELIAL GROWTH FACTOR AS A PREDICTOR OF RESPONSE TO THE COMBINED THERAPY WITH SORAFENIB AND TRANSARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
Authors: D. Lee, Y.-H. Chung, J.A. Kim, J.-H. Lee, E.-S. Shin, J.-H. Shim, H.C. Lee, J.H. Yoon, B.I. Kim, S.H. Bae, K.C. Koh, S.H. Ryu, N.-H. Park
Journal: Journal of Hepatology (2013)
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
Authors: A. Drilon, I. Bergagnini, L. Delasos, J. Sabari, K.M. Woo, A. Plodkowski, L. Wang, M.D. Hellmann, P. Joubert, C.S. Sima, R. Smith, R. Somwar, N. Rekhtman, M. Ladanyi, G.J. Riely, M.G. Kris
Journal: Annals of Oncology (2016)

RET rearrangements are targetable, oncogenic lung cancer drivers. While previous series have shown durable clinical benefit with pemetrexed-based therapies in ALK- and ROS1-rearranged lung cancers, the benefits of pemetrexed-based treatments in patients with RET-rearranged lung cancers relative to other genomic subsets have not previously been explored.A retrospective review of patients with pathologically confirmed stage IIIB/IV lung adenocarcinomas and evidence of a RET, ROS1, or ALK rearrangement, or a KRAS mutation was conducted. Patients were eligible if they received treatment with pemetrexed alone or in combination. The primary outcome of progression-free survival (PFS), and secondary outcomes of overall response rate (ORR, RECIST v1.1), time to progression (TTP), and time to treatment discontinuation were compared between RET-rearranged and groups of ROS1-rearranged, ALK-rearranged, and KRAS-mutant lung cancers.We evaluated 104 patients. Patients with RET-rearranged lung cancers (n = 18) had a median PFS of 19 months [95% confidence interval (CI) 12-not reached (NR)] that was comparable with patients with ROS1- (23 months, 95% CI 14-NR, n = 10) and ALK-rearranged (19 months, 95% CI 15-36, n = 36) lung cancers, and significantly improved compared with patients with KRAS-mutant lung cancers (6 months, 95% CI 5-9, P < 0.001, n = 40). ORR (45%), median TTP (20 months, 95% CI 17-NR), and median time to treatment discontinuation (21 months, 95% CI 6-NR) in patients with RET-rearranged lung cancers were not significantly different compared with patients with ALK- and ROS1-rearranged lung cancers, and improved compared with patients with KRAS-mutant lung cancers.Durable benefits with pemetrexed-based therapies in RET-rearranged lung cancers are comparable with ALK- and ROS1-rearranged lung cancers. When selecting therapies for patients with RET-rearranged lung cancers, pemetrexed-containing regimens should be considered.
SAT0260 Understanding limitations in at-work productivity in patients with active as: Larger contribution from medical factors compared to work related factors:
Authors: A. Boonen, C. Boone, A. Albert, H. Mielants
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> It is increasingly recognized that restrictions in work productivity while at work can be a predictor of future sick leave and withdrawal from labour force. At work productivity is a complex outcome and in addition to the physical impairments, also the environmental and personal context of the patients might contribute to work outcome. However, there are only limited data that help to understand the relative importance of these factors with regard to worker participation in patients with active AS with a paid work <h3>Objectives</h3> To understand contribution of health-related and work-related contextual factors on at work productivity restrictions in patients with AS with active disease. <h3>Methods</h3> Patients who were eligible to start a biological and working for pay, completed a questionnaire on health (BASDAI, BASFI), the Work Productivity &amp; Activity Impairment scale (WPAI) to assess absence and limitations in work productivity the last 7 days, and a large number of work characteristics comprising type of work, characteristics of workplace, satisfaction with contact with colleagues and importance of work in life. Multivariable regression models were computed to retrieve the model that explains best,which work related factors contributed to at work productivity limitations after adjusting for demographic (age and gender) and disease characteristics (disease duration, BASDAI, BASFI). <h3>Results</h3> 73 patients were included. 36 (49%) were male, age was 38 (sd:9) years, (sd:8.6) Disease duration (symptoms) was 10.8years, BASDAI 6.0 (1.7) and BASFI 5.2 (1.1). Patients worked on average 38 hours per week. 45 (63%) had a mainly manual profession, importance of work for life was 8.1 (1.9) (10 max) and quality of contact with colleagues was 8.0 (1.3) (max 10). 10 patients had been absent of which 6 (9%) due to AS. WPAI productivity limitations while at work was 48.7% (23.7). The table presents the best fitting model for at work productivity limitations. <h3>Conclusions</h3> For patients with AS that are eligible to start a biological, work is important for their life. Patients incur substantial restrictions in at work productivity. In addition to female gender and BASFI, the quality of contact with the colleagues was the only work related factor that contributed significantly to limitations in at work productivity. This offers additional opportunities to improve work outcome <h3>Disclosure of Interest</h3> A. Boonen Grant/Research support from: Amgen, Abbott, Speakers Bureau: Pfizer, C. Boone Employee of: Pfizer, A. Albert: None Declared, H. Mielants Speakers Bureau: Astra Zeneca, MSD, Pfizer
Abstract P5-05-11: The Cellular Impact of HuR (Human (Hu) Antigen R) in Breast Cancer Cells on the Growth and Invasion <i>In Vitro</i> and the Expression of Cyclin D1 and MMP-9
Authors: Z Yuan, AJ Sanders, L Ye, Y Wang, WG. Jiang
Journal: Cancer Research (2010)

Abstract Introduction: HuR, a ubiquitously expressed member of the Hu family, selectively binds and stabilizes ARE-containing mRNAs encoding proto-oncogenes, cell cycle regulators, cytokines and growth factors. The role of HuR and its cellular function in breast cancer remains unclear. In the present study, we aimed to provide new insights into the molecular and cellular implication of HuR in breast cancer. Materials and methods. We first constructed a set of anti-HuR ribozyme transgenes that targeted human HuR. Breast cancer cells were transfected with the transgene, in order to establish new sublines with HuR expression knocked down. Cell growth and invasiveness were investigated using in vitro cell models. The expression of cyclin-D1 and MMP2 were determined using immunocytochemistry, Western blotting and polymerase chain reaction. Results: Here, we show that MCF7 and MDA-MB-231 cells breast cancer cells stability transfected with a hammerhead ribozyme transgene specifically targeted to HuR (MCF7HuRKO and MDA-MB-231HuRKO) have a reduction in HuR expression both at mRNA and protein levels. Using these new sublines of breast cancer cells, the in vitro growth was evaluated. We showed that that HuR knockdown dramatically reduced cell growth in MCF7 cells (P &amp;lt; 0.001) and to a lesser degree reduced that in MDA MB 231 cells. We further demonstrated that reduction of HuR in MDA MB 231 cells (MDA-MB-231HuRKO) resulted in a significant reduction of the in vitro invasiveness in MDA-MB-231 cells (P &amp;lt; 0.001), although the same failed to occur to MCF-7 cells. Furthermore, we found that the decreased cell growth rate in MCF7 cells following HuR knockdown was seen together with a reduction in cyclin D1 transcript and protein levels. It was also interest to observe that the change in invasiveness in MDA-MB-231 cells after HuR knockdown was accompanied by a decrease in MMP-9 levels. Conclusion: Our study shows that targeting HuR can influences breast cancer cell growth and invasion and suggests a role for HuR in vitro in enhancing breast cancer cell growth and invasion. These changes may be facilitated through changes in the level of cyclin D1 and MMP-9. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-05-11.
Splenic laceration following ERCP
Authors: A. Paredes, A. Williams, A. Vertrees, C. Womeldorph
Journal: Endoscopy (2013)

A 39-year-old otherwise healthy woman presented to the hospital with acute cholecystitis and underwent a laparoscopic cholecystectomy. The procedure was technically difficult due to a severely inflamed gallbladder with adherent omentum. There was poor visualization of the cystic duct and bile duct junction, and a subtotal cholecystectomy was carried out. A surgical drain was left at the previous gallbladder bed. On postoperative day 3, the drain output had increased and changed to bilious drainage. On examination, the patient appeared uncomfortable and there were normal active bowel sounds with appropriate tenderness over the port sites. The fluid from the surgical drain tested high for bilirubin, favoring a bile leak.
The Practice and Teaching of Surgery in Veterans Administration Hospitals
Authors: J. Englebert Dunphy
Journal: New England Journal of Medicine (1949)

THE present Department of Medicine and Surgery in the Veterans Administration is to a considerable extent an achievement of a late member of this society, Dr. Elliott Carr Cutler. He was among the first to insist that if the Veterans Administration hospitals were under the aegis of the Universities, the highest standards of care would be assured for veterans and at the same time badly needed facilities for medical and surgical training would be provided for the many doctors whose education had been interrupted by the war. His unselfish devotion to the cause of the veteran, particularly the veteran doctor, . . .
415 HEPATIC STELLATE CELL AS A SOURCE FOR HEPATOCYTE DIFFERENTIATION BUT NO HEPATIC FIBROSIS DEVELOPMENT
Authors: A. Gumerova, A. Shafigullina, A. Trondin, M. Titova, M. Kaligin, I. Gazizov, D. Andreeva, S. Abdulkhakov, A. Kiassov
Journal: Journal of Hepatology (2012)
SP0100 Networking in Basic Research
Authors: B. Prakken
Journal: Annals of the Rheumatic Diseases (2013)

<h3></h3> The days that scientists could work alone in an isolated laboratory inventing new strategies and developing novel therapies are long gone. Modern science needs collaboration, networking. And not only modern science; in fact, even long before our current facebook and internet era, medical scientists worked close together by discussing hypotheses and shared information. Paradoxically, despite all the immense opportunities of collaboration thanks to all modern communication possibilities, sharing data and collaborating has not necessarily become easier. Instead, there are even developments that obstruct collaboration seriously, such as the pressure to ‘publish or perish’, preferably with authors of a one’s own institute on the magical spots of first or last author. These and other developments (including pressure from granting agencies, national regulations and other legal &amp; ethical requirements have hampered collaboration and form a serious obstacle in further progress. To change this, one needs a paradigm shift; the focus should be on what we want to achieve for the development of biomedical science in the field of arthritis, and less focus on the individual contributions of each group. In other words: it will be better to have a small part of a big pie, instead of a tiny pie just for yourself. Luckily, a number of new initiatives have sprouted in the field of childhood arthritis to achieve exactly this. These new initiatives, such as UCAN (http://ucanetwork.com), UCAN-U (www.ucan-u.org), SHARE, Pharmachild and the EU Marie Curie program EUTRAIN (www.eutrain-network.eu) offer new and excellent possibilities for networking open for everyone who wants to contribute. <h3>Disclosure of Interest</h3> None Declared
SAT0258 Identification of axial spondyloarthritis among patients with chronic back pain in primary care – does determination of HLA B27 improve the performance of clinical assessments of inflammatory back pain?
Authors: A. Braun, E. Saracbasi, J. Grifka, U. Kiltz, J. Schnittker, J. Braun
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The value of a combination of items defining inflammatory back pain (IBP) to screen for axial spondyloarthritis (SpA) in primary care has recently been studied. However, whether and how measurement of the HLA B27 status contributes to that is not clear. <h3>Objectives</h3> To study the additional value of HLA B27 determination as screening parameters for axial SpA in a cohort of patients with chronic back pain. <h3>Methods</h3> Consecutive patients &lt;45 years (n=950) with back pain &gt;2 months who presented to orthopedic surgeons (n=143) were randomized based on 4 primary key questions related to inflammatory back pain (IBP) for referral to rheumatologists (n=36) who made the diagnosis. HLA B27 was either assessed in primary or in secondary care. The primary outcome was the predictive value of a combination of items for a diagnosis of axial SpA. Logistic regression analyses and modeling techniques were used for the statistical analyses. <h3>Results</h3> Rheumatologists saw 322 randomly selected representative patients, mean age 36 years (y), 50% female, median duration of back pain 30 months: 113 patients were diagnosed as axial SpA (35%), 62% B27+, 47 as ankylosing spondylitis (AS, 15%), 66 as non-radiographic axial SpA (nr-axSpA, 21%). Major differences between AS and nr-axSpA have been described. Excluding HLA B27 from the analysis led to a list of criteria ≥4 of which had a sensitivity and specificity of 58.4 and 70.8%, respectively (area under ROC 69%). Adding HLA B27 to the analyses induced changes in the list of relevant items: past/present enthesitis came in, and the sensitivity (68.1%) but not the specificity (68.4%) of the criteria list improved (area under ROC 73.8%). <h3>Conclusions</h3> This study shows that patients with axial SpA can be identified by different methods in primary care. Combining HLA B27 and clinical items indicative of IBP increased the likelihood of having axial SpA in primary care. <h3>References</h3> Braun A, Saracbasi E, Grifka J, Schnitker J, Braun J. Identifying patients with axial spondyloarthritis in primary care: how useful are items indicative of inflammatory back pain? Ann Rheum Dis 2011;70:1782-7. <h3>Disclosure of Interest</h3> None Declared
Ga-68-DOTA-NOC PET/CT Reveals Active Graves' Orbitopathy in a Single Extraorbital Muscle
Authors: Robert Pichler, Michael Sonnberger, Claudia Dorninger, Hamid Assar, Tatjana Stojakovic
Journal: Clinical Nuclear Medicine (2011)

A 53-year-old woman with clinical history of multiple stroke presented with bilateral chemosis and vertical paresis of the right eye. Ophthalmologic examination showed partial atrophy of the right optical nerve, without exophthalmos. Sonography presented a pattern suggestive of autoimmune thyropathy. Laboratory revealed subclinical hyperthyroidism, and mildely elevated thyrotropin receptor antibody to 1.3 U/l. Graves' thyroid disease and concomitant ophthalmopathy was assumed. Head and neck Ga-68-DOTA-NOC PET/CT demonstrated marked accumulation at the thyroid and the right rectus inferior muscle. This finding corresponded to an isolated muscular enlargement seen with CT and MRI and representing active endocrine orbitopathy at this single location.
FRI0459 Characteristics and Long-Term Outcome of 122 Patients with Takayasu Arteritis
Authors: C. Comarmond, T. Mirault, P. Cluzel, F. Koskas, L. Chiche, J. Gaudric, E. Messas, P. Cacoub, D. Saadoun
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Takayasu arteritis (TA) is a chronic inflammatory disease that primarily affects large vessels, such as the aorta and its main branches. <h3>Objectives</h3> To report clinical features, morphologic findings, treatment and long-term outcome of a large cohort of patients with TA. <h3>Methods</h3> We performed a retrospective multicenter study of characteristics and outcome of 122 patients with TA fulfilling the American College of Rheumatology criteria. <h3>Results</h3> The median age [Q1; Q3] at onset of symptoms was 35.4 [24.4; 46.3] years and with a predominance of females (n=103, 84.4%). The median delay of diagnosis was 10 [0; 46.25] months. The most common clinical findings were vascular bruits (n=66, 54.1%), upper extremity blood pressure discrepancy &gt;10 mm Hg (n=57, 46.7%), and unequal or absent pulses (n=55, 45.1%). Major complications at diagnosis were hypertension (n=41, 33.6%), aortic regurgitation (n=24, 19.7%), aneuvrysm (n=30, 24.6%) and retinopathy (n=3, 2.1%). Fifty five (45%) patients had extensive disease at diagnosis according to Numano type V. Twenty four (19.7%) patients had another inflammatory or auto-immune disease associated to TA. Stenotic lesions were 3.1-fold more common than were aneuvrysms (77.9% versus 24.6%, respectively). Revascularization procedure was required for 53 (43.4%) patients. The median delay between diagnosis and first surgery or endovascular intervention was 5 [0; 17.5] months. Medical therapy (i.e. corticosteroids) was prescribed in 107 (87.7%) patients. The median delay in initiation of corticosteroids was 1 [0; 5] months. Eighty one (66.4%) patients required additional immunosuppressive agent. The median delay in initiation of the first immunosuppressor was 11 [2; 29.5] months. Fifty four (44.3%) patients relapsed after a median follow-up of 64.5 [24.9; 124.5] months. The median relapse-free survival was 16 [7; 62.25] months. <h3>Conclusions</h3> Most patients with TA require prolonged and intensive medical therapy. However, relapse and revascularization are frequents, occurring in nearly half of patients. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5926
Abstract 1389: Cyr61 increases cell migration in human oral cancer cells through FAK, ERK and NF-κB pathways
Authors: Nuo-Yi Yu, Jing-Yuan Chuang, Chin Hsuan Hsieh, Chih-Hsin Tang
Journal: Cancer Research (2011)

Abstract Cysteine-rich 61 (Cyr61), from the CCN gene family, is a secreted and matrix-associated protein, which is involved in many cellular activities such as growth and differentiation. Most of CCN family can regulate the cell motility, division and adhesion. However, the effect of Cyr61 on migration activity in human oral squamous carcinoma cells is mostly unknown. Here, we found that Cyr61 increased the migration in human oral squamous carcinoma cells (SCC-4 cells). Activations of focal adhesion kinase (FAK), extracellular signal-regulated kinase (ERK) and NF-κB pathways after Cyr61 treatment was demonstrated, and Cyr61-induced migration activity was inhibited by specific inhibitor of ERK and NF-κB cascades. Transfection of cells with FAK, ERK, IKKα(IkappaB kinase alpha) and IKKβ mutant also reduced Cyr61-mediated cancer migration. Taken together, our results suggest that Cyr61 acts through FAK/ERK, which in turn activates NF-κB, contributing to the migration of human oral squamous carcinoma cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1389. doi:10.1158/1538-7445.AM2011-1389
STENT THROMBOSIS AFTER PERCUTANEOUS TREATMENT FOR AORTIC COARCTATION
Authors: Fernando Inarra-Talboy, Hugo Rodriguez Zanella, Ricardo Gorocica Romero, Luis Marroquin Donday, Jesus Barrios, Salomón Rivera Peralta, Jose Briseno, Alexandra Arias-Mendoza, Carlos Martinez-Sanchez, Erick Alexanderson Rosas
Journal: Journal of the American College of Cardiology (2015)
P148 DONOR SPECIFIC ANTIBODIES AGAINST HLA CLASS II AND C4D-POSITIVITY: RISK FACTORS FOR LIVER ALLOGRAFT FIBROSIS
Authors: S. Iacob, V.R. Cicinnati, M. Lindemann, F.M. Heinemann, A. Radtke, G.M. Kaiser, I. Kabar, H.H.J. Schmidt, H.A. Baba, S. Beckebaum
Journal: Journal of Hepatology (2014)
PTU-185 Novel techniques for assessing oesophago-pharyngeal reflux in patients with hoarseness and suspected laryngopharyngeal reflux
Authors: J O Hayat, E Yazaki, A T Moore, L A C Hicklin, P W Dettmar, J-Y Kang, D Sifrim
Journal: Gut (2012)

<h3>Introduction</h3> It is suggested that hoarseness along with typical signs on laryngoscopy can be caused by oesophago-pharyngeal reflux, often referred to as LPR. New methods are proposed to assess pharyngeal exposure to gastric contents. They are suggested to measure (1) liquid or mixed gas-liquid acid and non-acid reflux (HMII-pH), (2) aerosolized acid reflux (Dx-pH measuring system, Restech), and (3) presence of pepsin in saliva. We <b>aimed</b> to quantify pharyngeal exposure to gastric contents in patients with hoarseness and healthy controls using the above techniques. <h3>Methods</h3> 21 patients with hoarseness and a positive laryngoscopy (mean age: 51 range: 23–75) and 10 asymptomatic controls (mean age: 26, range: 21–34) underwent simultaneous HMII-pH monitoring, oropharyngeal pH monitoring and saliva pepsin sampling. The HMII-pH catheter was located with impedance sensors in the oesophageal body, 3–5 cm distal and 0–2 cm proximal to the UOS. The Dx-pH catheter was located posterior to the uvula and pepsin in saliva was measured using an in vitro device utilising two pepsin monoclonal antibodies (PepTest) at five different times during the 24-h period. Patients were studied “off” PPI. <h3>Results</h3> Healthy controls had (1) no liquid or mixed gas/liquid reflux in the pharynx, (2) two controls had +ve Dx-pH and (3) two controls had more than one saliva sample +ve for pepsin with the other tests negative. Patients were classified into four groups: (a) all tests +ve (n=2); (b) two tests +ve (MII-pH + pepsin (n=5) or MII-pH + Dx-pH (n=3); (c) all tests negative (n=5) and (d) patients with +ve Dx-pH or pepsin without evidence of HMII detected reflux. These patients were considered negative (n=6). Dx-pH drops were poorly associated with HMII-pH reflux. 11% of Dx-pH drops to pH&lt;4, 15% of pH drops to pH&lt;5 and 10% of pH drops to pH&lt;5.5 coincided with HMII detected liquid or gas reflux in the oesophageal body. The detection of pepsin in saliva occurred in 7/10 patients with acid or non-acid HMII detected reflux. Positive pepsin saliva samples were preceded by more reflux events in the previous 60 min 3 (1–4) than negative samples 0 (0–2) p&lt;0.0001. <h3>Conclusion</h3> We identified a subgroup of patients with hoarseness with objective detection of oesophago-pharyngeal reflux (10/21). (b) the majority of oropharyngeal pH drops detected by Dx-pH do not correlate with retrograde flow (liquid or gas) in the oesophageal body. (c) Detection of pepsin in saliva suggests the likelihood of reflux episodes in the previous 60 min. <h3>Competing interests</h3> None declared.
EFFICACY AND SAFETY OF COLCHICINE FOR PREVENTION OF PERICARDITIS AND CARDIAC TAMPONADE: AN UPDATED META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Authors: Amartya Kundu, Partha Sardar, Sreeparna Ghosh, Saurav Chatterjee, Wilbert Aronow
Journal: Journal of the American College of Cardiology (2016)
Abstract 2349: New Insights into the Mechanism of Chronic Atrial Fibrillation in Patients
Authors: Ivan Cakulev, Seungyup Lee, Jayakumar Sahadevan, Celeen Khrestian, Albert Waldo
Journal: Circulation (2009)

Introduction: The mechanism(s) of chronic atrial fibrillation (AF) in humans is/are not well understood. We performed epicardial mapping of chronic AF in patients undergoing open heart surgery to test the hypothesis that chronic AF is due to 1or more drivers. Methods: Seven patients with chronic AF (1 month to >15 years duration) were mapped for a duration of 1 to 5 minutes during AF. Atrial electrograms (AEGs) were simultaneously recorded from 404 –512 epicardial electrodes arranged in bipoles along with ECG lead II. 40 – 60 secs were analyzed per patient in multiple segments of 10 to 20 sec each. For all segments, both FFT and cycle length (CL) variability were analyzed for each site. Regular activity at each site was defined as the mean CL +/− 15 ms. Results: Sites with regular activity (CL’s range 165–215 ms) were found in 6 out of 7 patients; Two or more sites with regular activity but with distinct CL’s existed simultaneously; Each patient had 3– 4 dominant peak FFT frequencies; Most of the sites of...